Keyphrases
Early Parkinson's Disease
100%
Rasagiline
100%
Delayed Start
100%
Placebo
33%
Unified Parkinson's Disease Rating Scale (UPDRS)
33%
United States
11%
Group Randomized
11%
Clinical Trials
11%
Parkinson's Disease
11%
Patients with Parkinson's Disease
11%
Change of Measure
11%
Canada
11%
Functional Decline
11%
Dopaminergic Therapy
11%
Early Initiation
11%
Efficacy Analysis
11%
Rasagiline Mesylate
11%
Monoamine Oxidase B Inhibitors
11%
Late Initiation
11%
Disability Progression
11%
Pharmacology, Toxicology and Pharmaceutical Science
Rasagiline
100%
Parkinson's Disease
100%
Placebo
30%
Clinical Trial
10%
Preclinical Study
10%
Dopamine Receptor Stimulating Agent
10%
Symptom
10%
Amine Oxidase (Flavin Containing)
10%
Neuroscience
Parkinson's Disease
100%
Rasagiline
100%
Placebo
30%
Dopaminergic
10%
Monoamine Oxidase
10%